Elamipretide + nicotinamide mononucleotide
Elamipretide + nicotinamide mononucleotide has been studied in 2 papers since 2020: none in people yet, 2 in animals. The research so far is in animals. The newest paper, Apr 22, 2024: “Metabolite accumulation from oral NMN supplementation drives aging-specific kidney inflammation”.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Institute on Aging and others
- Animals2
What did studies of Elamipretide + nicotinamide mononucleotide find?
2Studies of Elamipretide + nicotinamide mononucleotide measured 2 outcomes; the most studied are Il1b and Ccl2 expression (1 study) and NAD+ (1).
Il1b and Ccl2 expression
downin mice1
1 study
Il1b and Ccl2 expression
downin mice1
Elamipretide + nicotinamide mononucleotide decreases Il1b and Ccl2 expression in mice.
“ELAM+NMN-treated aged mice accumulated uremic toxins like NMN-only aged mice, but reduced IL-1-beta; and Ccl2 kidney mRNA.”
Animalsaged micekidneyelamipretide 3 mg/kg/day + NMN 300 mg/kg/day8 weeksmales
Metabolite accumulation from oral NMN supplementation drives aging-specific kidney inflammation
bioRxiv : the preprint server for biologyPreprint
NAD+
upin mice1
1 study
NAD+
upin mice1
Elamipretide + nicotinamide mononucleotide increases NAD+ in mice.
“only the Combined treatment resulted in significantly greater steady-state NAD(H) levels”
Animalsaged heartsheart
SS-31 and NMN: Two paths to improve metabolism and function in aged hearts
Aging cell